Antiproteases in the treatment of acute necrotizing pancreatitis: Continuous regional arterial infusion

Journal of the Pancreas

Volumn 8, Issue 4, 2007, Pages 526-532

  Takeda, Kazunori ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Acute necrotizing; FOY 305; Gabexate; Infusions; Intra arterial; Ischemia; Nafamostat; Pacreatitis; Protease inhibitors; Vasoconstriction

Indexed keywords

ANTIBIOTIC AGENT; ENDOTHELIN 1; GABEXATE MESILATE; INTERLEUKIN 6; NAFAMSTAT MESILATE; PROTEINASE INHIBITOR; THROMBIN;

ACUTE HEMORRHAGIC PANCREATITIS; ANGIOGRAPHY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTINUOUS REGIONAL ARTERIAL INFUSION; CONTRAST ENHANCEMENT; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ADMINISTRATION ROUTE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; ENZYME INHIBITION; HUMAN; ISCHEMIA; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PANCREAS NECROSIS; PERFUSION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TISSUE DISTRIBUTION; VASOSPASM;

HUMANS; INFUSIONS, INTRA-ARTERIAL; ISCHEMIA; PANCREAS; PANCREATITIS, ACUTE NECROTIZING; PROTEASE INHIBITORS;

EID: 34547959588     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Jerius H, Beall A, Woodrum D, Epstein A, Brophy C. Thrombin-induced vasospasm: cellular signaling mechanism. Surgery 1998; 123:46-50.
2. Knoepp L, Bagwell CD, Garlich P, Brophy CM. Thrombin contraction of vascular smooth muscle: implications for vasospasm. Int J Surg Investig 1999; 1:285-90.
3. Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexate mesilate (Foy) in the treatment of acute pancreatitis. Pancreas 1987; 6:698-700.
4. Freise J, Melzer P, Schmidt FW, Horbach L. Gabexate mesilate in the treatment of acute pancreatitis. Results of a Hannover multicenter double-blind study with 50 patients. Z Gastroenterol 1986; 24:200-211.
5. Pederzoli P, Cavallini G, Falconi M, Bassi C. Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.). A prospective, randomized, double-blind multicenter study. Int J Pancreatol 1993; 14:117-24.
6. Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockmann F, Adler G, et al. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology 1993; 104:1165-70.
7. Chen HM, Chen JC, Hwang TL, Jan YY, Chen MF. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology 2000; 47:1147-50.
8. Andriulli A, Leandro G, Clemente R, Festa V, Caruso N, Annese V, et al. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the treatment of acute pancreatitis. Aliment Pharmacol Ther 1998; 12:237-45.
9. Yamauchi J, Takeda K, Shibuya K, Sunamura M, Matsuno S. Continuous regional application of protease inhibitor in the treatment of acute pancreatitis. An experimental study using closed duodenal obstruction model, in dogs. Pancreatology 2001; 1:662-7.
10. Satoh H, Harada M, Tashiro S, Shiroya T, Imawaka H, Machii K. The effect of continuous arterial infusion of gabexate mesilate (FOY-007) on experimental acute pancreatitis. J Med Invest 2004; 51:186-93.
11. Mikami Y, Takeda K, Matsuda Y,, Qiu-Feng H, Fukuyama S, Egawa S, et al. Rat experimental model of continuous regional arterial infusion of protease inhibitor and its effects on severe acute pancreatitis. Pancreas 2005; 30:248-53.
12. Roesch J, Bret J. Arteriography of the pancreas. Am J Roentgenol Rad Ther Nucl Med 1965; 94:182-93.
13. Reuter SR, Redman HC, Joseph RR. Angiographic findings in pancreatitis. Am J Roentgenol Rad Ther Nucl Med 1969; 107:56-64.
14. Tylen U, Arnesjo B. Angiographic diagnosis of inflammatory disease of the pancreas. Acta Radiol Diagn (Stockh) 1973; 14:21540.
15. Inoue K, Hirota M, Kimura Y, Kuwata K, Ohmuraya M, Ogawa M. Further evidence for endothelin as an important mediator of pancreatic and intestinal ischemia in severe acute pancreatitis. Pancreas 2003; 26:218-223.
16. Inoue K, Hirota M, Beppu T, Ishiko T, Kimura Y, Maeda K, Ogawa M. Angiographic features in acute pancreatitis: The severity of abdominal vessel ischemic change reflects the severity of acute pancreatitis. JOP. J Pancreas (Online) 2003; 4:207-13.
17. Takeda. K, Mikami Y, Fukuyama S, Egawa S, Sunamura M, Ishibashi T, et al. Pancreatic ischemia associated with vasospasm in the early phase of human acute necrotizing pancreatitis. Pancreas 2005; 30:40-9.
18. Hirota M, Inoue K, Kimura Y, Mizumoto T, Kuwata K, Ohmuraya M, et al. Non-occlusive mesenteric ischemia and its associated intestinal gangrene in acute pancreatitis. Pancreatology 2003; 3:316-22.
19. Yasuda T, Takeyama Y, Ueda T, Hori Y, Nishikawa J, Kuroda Y. Nonocclusive visceral ischemia associated with severe acute pancreatitis. Pancreas 2003; 26:95-7.
20. Eto M, Barandier C, Rathgeb L, Kozai T, Joch H, Yang Z, Luscher TF. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res 2001; 89:583-90.
21. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 1981; 661:342-5.
22. Aoyama T, Ino Y, Ozeki M, Oda M, Sato T, Koshiyama Y, et al. Pharmacological studies of FUT-175, nafamostat mesilate. I. Inhibition of protease activity in vitro and in vivo experiments. Jpn J Pharmacol 1984; 35:203-27.
23. Iwaki M, Ino Y, Motoyoshi A, Ozeki M, Sato T, Kurumi M, Aoyama T. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol 1986; 41:155-62.
24. Kaller H, Patzschke K, Wegner LA, et al. Pharmacokinetic observations following intravenous administration of radioactively labeled aprotinin in volunteers. Eur J Drug Metab Pharmacokinet 1965; 3:79-85.
25. Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg 1996; 171:394-8.
26. Takeda. K, Matsuno S, Ogawa M, Watanabe S, Atomi Y. Continuous regional arterial infusion (CRAI) therapy reduces the mortality rate of acute necrotizing pancreatitis: results of a cooperative survey in Japan. J Hepatobiliary Pancreat Surg 2001; 8:216-20.
27. Takeda K, Yamauchi J, Shibuya K, Sunamura M, Mikami Y, Matsuno S. Benefit of continuous regional arterial infusion of protease inhibitor and antibiotic in the management of acute necrotizing pancreatitis. Pancreatology 2001; 1:668-73.
28. Imaizumi H, Kida M, Nishimaki H, Okuno J, Kataoka Y, Kida Y, et al. Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas 2004; 28:369-73.
29. Anai H, Sakaguchi H, Uchida H, Matsuo N, Tanaka T, Yoshioka T, et al. Continuous arterial infusion therapy for severe acute pancreatitis: correlation between CT arteriography and therapeutic effect. J Vasc Interv Radiol 1999; 10:1335-42.
30. Hayashi J, Kawarada Y, Isaji S, Yokoi H, Higashiguchi T. Therapeutic effects of continuous intraarterial antibiotic infusion in preventing pancreatic infection in experimental acute necrotizing pancreatitis. Pancreas 1996; 13:184-92.
31. Fukuyama S, Takeda K, Matsuda K, et al. Does intra-arterial infusion therapy ameliorate pancreatic perfusion? J Abdom Emerg Med 2005; 25:633-6.